Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Avid Bioservices Inc (NQ: CDMO )

14.25 USD +0.63 (+4.63%)
Official Closing Price Updated: 4:03 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Avid Bioservices Inc

< Previous 1 2 Next >
Avid Bioservices Announces Closing of Public Offering of Common Stock
From GlobeNewswire News Releases
Avid Bioservices Announces Pricing of Public Offering of Common Stock
From GlobeNewswire News Releases
Avid Bioservices Announces Proposed Public Offering of Common Stock
From GlobeNewswire News Releases
Avid Bioservices Announces Appointment of Jeanne Thoma to Board of Directors
From GlobeNewswire News Releases
Avid Bioservices Reports Financial Results for Second Quarter Fiscal 2021 and Recent Developments
From GlobeNewswire News Releases
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
From GlobeNewswire News Releases
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2021 After Market Close on December 2, 2020
From GlobeNewswire News Releases
Contract Development & Manufacturing Organization (CDMO) Market Worth Observing Growth by 2026: Aenova, Siegfried, Recipharm, Strides Shasun
Edison, NJ -- (SBWIRE) -- 11/18/2020 -- Keep yourself up-to-date with latest market trends and maintain a competitive edge by sizing up with available business opportunity in Contract Development &... 
From SBWire - Latest Press Releases
Avid Bioservices Announces Move to Virtual-Only Annual Meeting of Stockholders on October 20, 2020
From GlobeNewswire News Releases
Avid Bioservices to Participate in 18th Annual Morgan Stanley Global Healthcare Conference
From GlobeNewswire News Releases
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2020 and Recent Developments
From GlobeNewswire News Releases
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
From GlobeNewswire News Releases
Avid Bioservices Selected by Mapp Biopharmaceutical, Inc. for Clinical Development of Novel Human Monoclonal Antiviral Antibody
From GlobeNewswire News Releases
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2021 After Market Close on September 1, 2020
From GlobeNewswire News Releases
Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine
Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine 
From Business Wire News Releases
Avid Bioservices Selected By Iovance Biotherapeutics to Lead Process Development Through CGMP Manufacturing of Novel IL-2 Analog, IOV-3001
From GlobeNewswire News Releases
Avid Bioservices and Argonaut Manufacturing Services Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Process Development, Drug Substance Manufacturing and Drug Product Par
Argonaut’s Clinical Fill-Finish Capabilities to Complement Avid’s Upstream and Downstream Process Development and Biologics Manufacturing Services in Supporting Developers of Biologic Therapeutics 
From GlobeNewswire News Releases
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2020 and Recent Developments
From GlobeNewswire News Releases
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2020 After Market Close on June 30, 2020
From GlobeNewswire News Releases
Avid Bioservices Names Nicholas Green as President and Chief Executive Officer
Seasoned Executive Brings More than 30 Years of Pharmaceutical and Healthcare Services Industry Experience to Lead Avid Through Next Phase of Growth and Expansion 
From GlobeNewswire News Releases
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
From GlobeNewswire News Releases
Avid Bioservices and Aragen Bioscience Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Solution for Cell Line and Process Development through Commercial Manufacturing
Full Service “Sequence-to-Manufacturing” Offering Designed to Drive Efficiencies and Reduce Overall Timelines for Delivering Early-Stage CGMP Bulk Drug Substances 
From GlobeNewswire News Releases
Avid Bioservices Announces Appointment of Two Senior Directors of Business Development with Responsibility for North America, Europe and Asia
From GlobeNewswire News Releases
Avid Bioservices Receives Five 2020 CMO Leadership Awards
From GlobeNewswire News Releases
Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2020 and Recent Developments
From GlobeNewswire News Releases
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
From GlobeNewswire News Releases
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2020 After Market Close on March 10, 2020
From GlobeNewswire News Releases
Avid Bioservices Appoints Timothy Compton as Chief Commercial Officer
Company Adds Seasoned Professional with Over 20 Years of Commercial Operations and Sales Team Management Experience 
From GlobeNewswire News Releases
Biotech Advancements In The Immuno-Oncology Field For Pediatric and Adult Brain Tumors
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Biotech Advancements in the Immuno-Oncology Field for Pediatric and Adult Brain Tumors
Financialnewsmedia.com News Commentary 
From PR Newswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.